Brief Overview: Patent dispute complexity is further complicated by the increasingly common occurrence of multiple, sequential patent infringement proceedings involving the same drug product and the same parties, referred to as “serial patent litigation”. The impact of serial patent litigation extends well into the marketplace in the form of delayed or deterred generic and biosimilar entry, which ultimately influences drug prices, innovation strategies and competition. Understanding these trends will be crucial for assessing the future landscape of pharmaceutical litigation.
Authors:
|
|
|
|
|
|
|
|
|
|
|
|